1. Scrip
  2. >>New Products

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

 
• By Joseph Haas

Xolremdi was OKed as the first drug for WHIM syndrome and X4 set pricing at $372,000-$496,000 a year, but the drug’s bigger opportunity may be in chronic neutropenia.

FDA Approved
X4 gets its first drug approval, in ultra-rare WHIM syndrome

With its first drug approval and the first approved therapy for the ultra-rare immunodeficiency disorder WHIM syndrome, X4 Pharmaceuticals, Inc. told a 29 April investor call that while Xolremdi (mavorixafor) will be available immediately, it sees 2024 as a year for laying the groundwork for clinician understanding and payer acceptance of the drug.

Key Takeaways

  • About two years after a 20% staff cut, X4 gets its first FDA approval for Xolremdi in the rare immunodeficiency disorder WHIM syndrome.

  • The biotech sets pricing at $372,000-$496,000 per year and says early launch months will focus on setting up the market

Xolremdi is a once-daily capsule indicated in the US as a 400mg dose in patients weighing more than 50kg and dosed at 300mg in patients at or below 50kg. It will carry a wholesale acquisition cost of $496,000 for the higher dose and $372,000 for the lower dose

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.